Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage

被引：45

作者：

Seiffge, David J. ^{[1
,2
,3
]}

Kagi, Georg ^{[4
]}

Michel, Patrik ^{[5
]}

Fischer, Urs ^{[6
]}

Bejot, Yannick ^{[7
]}

Wegener, Susanne ^{[8
]}

Zedde, Marialuisa ^{[9
]}

Turc, Guillaume ^{[10
]}

Cordonnier, Charlotte ^{[11
]}

Sandor, Peter S. ^{[12
]}

Rodier, Gilles ^{[13
]}

Zini, Andrea ^{[14
]}

Cappellari, Manuel ^{[15
]}

Schadelin, Sabine ^{[16
]}

Polymeris, Alexandros A. ^{[1
,2
,3
]}

Werring, David ^{[17
,18
]}

Thilemann, Sebastian ^{[1
,2
,3
]}

Maestrini, Ilaria ^{[11
]}

Berge, Eivind ^{[19
,20
]}

Traenka, Christopher ^{[1
,2
,3
]}

Vehoff, Jochen ^{[4
]}

De Marchis, Gian Marco ^{[1
,2
,3
]}

Kapauer, Monika ^{[4
]}

Peters, Nils ^{[1
,2
,3
,21
]}

Sirimarco, Gaia ^{[5
]}

Bonati, Leo H. ^{[1
,2
,3
]}

Arnold, Marcel ^{[6
]}

Lyrer, Philippe A. ^{[1
,2
,3
]}

De Maistre, Emmanuel ^{[22
]}

Luft, Andreas ^{[8
]}

Tsakiris, Dimtrios A. ^{[23
]}

Engelter, Stefan T. ^{[1
,2
,3
,21
]}

机构：

[1] Univ Hosp Basel, Stroke Ctr, Petersgraben 4, CH-4031 Basel, Switzerland

[2] Univ Basel, Petersgraben 4, CH-4031 Basel, Switzerland

[3] Univ Hosp, Dept Clin Res, Dept Neurol, Basel, Switzerland

[4] St Gallen Cantonal Hosp, Dept Neurol, St Gallen, Switzerland

[5] Univ Hosp, Dept Neurol, Lausanne, Switzerland

[6] Inselspital Bern, Dept Neurol, Bern, Switzerland

[7] Univ Hosp, Dept Neurol, Dijon Stroke Registry, Dijon, France

[8] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland

[9] New Santa Maria Hosp, Inst Hospitalizat & Sci Care, Neurol Unit, Stroke Unit, Reggio Emilia, Italy

[10] St Anne Hosp, Natl Inst Hlth & Med Res, Dept Neurol, U894, Paris, France

[11] Univ Lille, Lille Univ Hosp Ctr, Natl Inst Hlth & Med Res, U1171,Degenerat & Vasc Cognit Disorders,Dept Neur, Lille, France

[12] Baden Cantonal Hosp, Dept Neurol, Baden, Switzerland

[13] Annecy Genevois Hosp Ctr, Dept Neurol, Epagny Metz Tessy, France

[14] Modena Univ Hosp, SAgostino Estense Hosp, Dept Neurosci, Stroke Unit, Modena, Italy

[15] Integrated Univ Hosp, USD Stroke Unit, DAI Neurosci, Verona, Italy

[16] Univ Hosp Basel, Clin Trial Unit, Basel, Switzerland

[17] UCL, Dept Brain Repair & Rehabil, Ctr Stroke Res, Inst Neurol, London, England

[18] Natl Hosp Neurol & Neurosurg, London, England

[19] Oslo Univ Hosp, Dept Internal Med, Oslo, Norway

[20] Oslo Univ Hosp, Dept Cardiol, Oslo, Norway

[21] Univ Basel, Univ Ctr Med Aging & Rehabil Basel, Felix Platter Hosp, Neurorehabil Unit, Basel, Switzerland

[22] Univ Hosp, Hematol Lab, Dijon, France

[23] Univ Hosp Basel, Diagnost Hematol, Basel, Switzerland

来源：

ANNALS OF NEUROLOGY | 2018年 / 83卷 / 03期

关键词：

HEALTH-CARE PROFESSIONALS; INTRAVENOUS THROMBOLYSIS; ORAL ANTICOAGULANTS; IV THROMBOLYSIS; FACTOR XA; MANAGEMENT; GUIDELINES; COMPLICATIONS; REVERSAL;

D O I：

10.1002/ana.25165

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

ObjectiveInformation about rivaroxaban plasma level (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban. MethodsIn a multicenter registry-based study (Novel Oral Anticoagulants in Stroke Patients collaboration; ClinicalTrials.gov: NCT02353585) of patients with stroke while taking rivaroxaban, we compared RivLev in patients with AIS and ICH. We determined how many AIS patients had RivLev100ng/ml, indicating possible eligibility for thrombolysis, and how many ICH patients had RivLev75ng/ml, making them possibly eligible for the use of specific reversal agents. We explored factors associated with RivLev (Spearman correlation, regression models) and studied the sensitivity and specificity of international normalized ratio (INR) thresholds to substitute RivLev using cross tables and receiver operating characteristic curves. ResultsAmong 241 patients (median age=80 years, interquartile range [IQR]=73-84; median time from onset to admission=2 hours, IQR=1-4.5 hours; median RivLev=89ng/ml, IQR=31-194), 190 had AIS and 51 had ICH. RivLev was similar in AIS patients (82ng/ml, IQR=30-202) and ICH patients (102ng/ml, IQR=51-165; p=0.24). Trough RivLev((137ng/ml)) occurred in 126/190 (66.3%) AIS and 34/51 (66.7%) ICH patients. Among AIS patients, 108/190 (56.8%) had RivLev100ng/ml. In ICH patients, 33/51 (64.7%) had RivLev75ng/ml. RivLev was associated with rivaroxaban dosage, and inversely with renal function and time since last intake (each p<0.05). INR1.0 had a specificity of 98.9% and a sensitivity of 25.7% to predict RivLev100ng/ml. INR1.4 had a sensitivity of 59.3% and specificity of 90.1% to predict RivLev75ng/ml. InterpretationRivLev did not differ between patients with AIS and ICH. Half of the patients with AIS under rivaroxaban had a RivLev low enough to consider thrombolysis. In ICH patients, two-thirds had a RivLev high enough to meet the eligibility for the use of a specific reversal agent. INR thresholds perform poorly to inform treatment decisions in individual patients. Ann Neurol 2018;83:451-459

引用

页码：451 / 459

页数：9

共 50 条

[1] When less is more (brain)comment on "Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage"
Lyden, Patrick D.
ANNALS OF NEUROLOGY, 2018, 83 (03) : 446 - 448
[2] Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke
Seiffge, David J.
Traenka, Christopher
Polymeris, Alexandros
Hert, Lisa
Fisch, Urs
Peters, Nils
De Marchis, Gian Marco
Guzman, Raphael
Nickel, Christian H.
Lyrer, Philipp A.
Bonati, Leo H.
Tsakiris, Dimitrios
Engelter, Stefan
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2017, 43 (01) : 112 - 116
[3] Acute Treatment of Blood Pressure After Ischemic Stroke and Intracerebral Hemorrhage
Jordan, J. Dedrick
Morbitzer, Kathryn A.
Rhoney, Denise H.
NEUROLOGIC CLINICS, 2015, 33 (02) : 361 - +
[4] Acute treatment costs of intracerebral hemorrhage and ischemic stroke in Argentina
Christensen, M. C.
Previgliano, I.
Capparelli, F. J.
Lerman, D.
Lee, W. C.
Wainsztein, N. A.
ACTA NEUROLOGICA SCANDINAVICA, 2009, 119 (04): : 246 - 253
[5] Managing high blood pressure during acute ischemic stroke and intracerebral hemorrhage
Appiah, Karen O.
Minhas, Jatinder S.
Robinson, Thompson G.
CURRENT OPINION IN NEUROLOGY, 2018, 31 (01) : 8 - 13
[6] Intracerebral hemorrhage risk after adjunct intraarterial thrombolysis in thrombectomy-treated acute ischemic stroke
Qureshi, Adnan I.
Huang, Yilun
Bhatti, Ibrahim A.
Gomez, Camilo R.
Hanley, Daniel F.
Ford, Daniel E.
Hassan, Ameer E.
Nguyen, Thanh N.
Spiotta, Alejandro M.
Veznedaroglu, Erol
Budzik, Ronald F.
Gupta, Rishi
Nogueira, Raul G.
Krajina, Antonin
Bartolini, Bruno
English, Joey
Baxter, Blaise
Liebeskind, David S.
JOURNAL OF NEUROIMAGING, 2024, 34 (06) : 773 - 780
[7] Glucose Control and Risk of Symptomatic Intracerebral Hemorrhage Following Thrombolysis for Acute Ischemic Stroke
Southerland, Andrew M.
Mayer, Stephan A.
Chiota-McCollum, Nicole A.
Bolte, Ashley C.
Pauls, Qi
Pettigrew, L. Creed
Bleck, Thomas P.
Conaway, Mark
Johnston, Karen C.
NEUROLOGY, 2024, 102 (09)
[8] Thrombolysis in an acute ischemic stroke patient with rivaroxaban anticoagulation A case report
Chao, Yen-Tung
Hu, Chaur-Jong
Chan, Lung
MEDICINE, 2019, 98 (08)
[9] Pilot Study of Remote Ischemic Conditioning in Acute Spontaneous Intracerebral Hemorrhage
Jarrahi, Abbas
Shah, Manan
Ahluwalia, Meenakshi
Khodadadi, Hesam
Vaibhav, Kumar
Bruno, Askiel
Baban, Babak
Hess, David C.
Dhandapani, Krishnan M.
Vender, John R.
FRONTIERS IN NEUROSCIENCE, 2022, 16
[10] Ischemic Stroke Prevention After Intracerebral Hemorrhage
Asad, Syed Daniyal
Kozberg, Mariel Gailey
CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, 2023, 25 (08) : 325 - 345

← 1 2 3 4 5 →